Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632088 | 0.77 | MAPT (0.52) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL3632085 | 0.77 | MAPT (0.52) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL943328 | 0.74 | LMNA (0.54) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL4729820 | 0.74 | LMNA (0.61) | MEN1KMT2ALMNAALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL944551 | 0.73 | LMNA (0.52) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL406034 | 0.69 | LMNA (0.59) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL23292561 | 0.69 | MAPT (0.59) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL9532230 | 0.69 | CYP2C19 (0.44) | MEN1KMT2ALMNAALDH1A1GAA | |
| SCHEMBL9532225 | 0.69 | CYP2C19 (0.44) | MEN1KMT2ALMNAALDH1A1GAA | |
| SCHEMBL6542484 | 0.68 | LMNA (0.61) | MEN1KMT2ALMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865753-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8835475-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8507493-B2 | Amide and amidine derivatives and uses thereof | ABBVIE INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8501794-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| CN-102272111-A | 1,2 -thiazol yl derivatives as cannabinoid receptor ligands | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2344463-A2 | 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7875640-B2 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-7872033-B2 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| WO-2010123838-A2 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010054024-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2146973-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130953-A2 | 2-IMIN0IS0THIAZ0LE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TBXA2R | MEN1 4351/4885KMT2A 2212/4885LMNA 2474/4885 |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | MEN1 1978/4885KMT2A 2829/4885LMNA 3575/4885 |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TRPV1 | MEN1 3535/4885KMT2A 2433/4885LMNA 2741/4885 |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | MEN1 3076/4885KMT2A 2410/4885LMNA 3709/4885 |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | MEN1 3208/4885KMT2A 1818/4885LMNA 4071/4885 |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | MEN1 3341/4885KMT2A 1801/4885LMNA 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.